<DOC>
	<DOCNO>NCT02255292</DOCNO>
	<brief_summary>Increasing line evidence support antitumourigenic effect cannabinoids , include cannabidiol ( CBD ) posses psychotropic effect D9-tetrahydrocannabinol ( THC ) . These include anti-proliferative pro-apoptotic effect know interfere several mechanism tumorgenesis . Yet , evidence clinical trial among cancer patient need . The aim current study evaluate impact CBD single treatment among cancer patient .</brief_summary>
	<brief_title>A Study : Pure CBD Single-agent Solid Tumor .</brief_title>
	<detailed_description />
	<criteria>Confirmed solid cancer Approved license use cannabis ( ministry health : Israel ) Progression available standard therapy / unfit standard therapy accord oncologist 's view Measurable disease determine RECIST Life expectancy least 6 month Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; = 2 Aged 18 year old Received cannabis therapy indication Previous systemic therapy le 3 week prior , present , acute toxicity &gt; grade 1 . Clinically significant cardiac disease history psychosis Pregnancy breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>